NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma
- 331 Downloads
NF45, also referred to as nuclear factor of activated T cells, has been reported to promote the progression of multiple cancer types. However, the expression and physiological significance of NF45 in pancreatic ductal adenocarcinoma (PDAC) remain largely elusive. In this study, we investigated the clinical relevance and potential role of NF45 expression in PDAC development. Western blot analysis revealed that NF45 was remarkably upregulated in PDAC tissues, compared with the adjacent non-tumorous ones. In addition, the expression of NF45 in 122 patients with PDAC was evaluated using immunohistochemistry. In this way, we found that NF45 was abundantly expressed in PDAC tissues, and the expression of NF45 was correlated with tumor size (p = 0.007), histological differentiation (p = 0.033), and TNM stage (p = 0.001). Importantly, patients with low levels of NF45 expression exhibited better postoperative prognosis as compared with those with high NF45 expression. Furthermore, using PDAC cell cultures, we found that interference of NF45 expression using siRNA oligos suppressed PDAC cell proliferation and retarded cell cycle progression. Moreover, depletion of NF45 impaired the levels of cellular cyclin E and proliferating cell nuclear antigen (PCNA). Conversely, overexpression of NF45 facilitated the cell growth and accelerated cell cycle progression. Our results establish NF45 as an important indicator of PDAC prognosis with potential utility as a therapeutic target in this lethal disease.
KeywordsNF45 Pancreatic ductal adenocarcinoma (PDAC) Prognosis Cell proliferation
We thank Dr. Martin Holcik of University of Ottawa for kindly offering us the pcDNA3-Flag-NF45 construct. This work was supported by the National Natural Scientific Foundation of China (No. 81072028) and Jiangsu Province’s Outstanding Medical Academic Leader program (No. LJ101135).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17:500–503. doi: 10.1038/nm.2344 PubMedCentralCrossRefPubMedGoogle Scholar
- 8.Sakamoto S, Aoki K, Higuchi T, Todaka H, Morisawa K, Tamaki N, Hatano E, Fukushima A, Taniguchi T, Agata Y (2009) The NF90–NF45 complex functions as a negative regulator in the microRNA processing pathway. Mol Cell Biol 29:3754–3769. doi: 10.1128/MCB.01836-08 PubMedCentralCrossRefPubMedGoogle Scholar
- 15.Faye MD, Graber TE, Liu P, Thakor N, Baird SD, Durie D, Holcik M (2013) Nucleotide composition of cellular internal ribosome entry sites defines dependence on NF45 and predicts a posttranscriptional mitotic regulon. Mol Cell Biol 33:307–318. doi: 10.1128/MCB.00546-12 PubMedCentralCrossRefPubMedGoogle Scholar
- 16.Haselmann V, Kurz A, Bertsch U, Hubner S, Olempska-Muller M, Fritsch J, Hasler R, Pickl A, Fritsche H, Annewanter F, Engler C, Fleig B, Bernt A, Roder C, Schmidt H, Gelhaus C, Hauser C, Egberts JH, Heneweer C, Rohde AM, Boger C, Knippschild U, Rocken C, Adam D, Walczak H, Schutze S, Janssen O, Wulczyn FG, Wajant H, Kalthoff H, Trauzold A (2014) Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology 146:278–290. doi: 10.1053/j.gastro.2013.10.009 CrossRefPubMedGoogle Scholar
- 20.Guan D, Altan-Bonnet N, Parrott AM, Arrigo CJ, Li Q, Khaleduzzaman M, Li H, Lee CG, Pe’ery T, Mathews MB (2008) Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in mitotic control. Mol Cell Biol 28:4629–4641. doi: 10.1128/MCB.00120-08 PubMedCentralCrossRefPubMedGoogle Scholar
- 21.Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO, Goggins M (2003) Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162:1151–1162. doi: 10.1016/S0002-9440(10)63911-9 PubMedCentralCrossRefPubMedGoogle Scholar
- 22.Cartier J, Berthelet J, Marivin A, Gemble S, Edmond V, Plenchette S, Lagrange B, Hammann A, Dupoux A, Delva L, Eymin B, Solary E, Dubrez L (2011) Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription. J Biol Chem 286:26406–26417. doi: 10.1074/jbc.M110.191239 PubMedCentralCrossRefPubMedGoogle Scholar
- 23.Bharadwaj U, Li M, Chen C, Yao Q (2008) Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res 6:1755–1765. doi: 10.1158/1541-7786.MCR-08-0095 PubMedCentralCrossRefPubMedGoogle Scholar
- 29.Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Moller P, Gschwend JE, Simmet T, Debatin KM, Fulda S (2009) Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 69:2425–2434. doi: 10.1158/0008-5472.CAN-08-2436 CrossRefPubMedGoogle Scholar